Immunologic and hematologic properties of antibodies to prothrombin and plasminogen in a mouse model

Lupus

Volumn 10, Issue 2, 2001, Pages 108-115

  Puurunen, M ^a   Palosuo, T ^a   Lassila, R ^a   Anttila, M ^a   Vaarala, O ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Antiphospholipid antibodies; Antiplasminogen antibodies; Antiprothrombin antibodies; Fibrinolysis; Lupus anticoagulant

Indexed keywords

AUTOANTIBODY; CARDIOLIPIN; CROSS REACTING ANTIBODY; GLYCOPROTEIN IB; PLASMINOGEN; PROTHROMBIN ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FIBRINOLYSIS; IMMUNE RESPONSE; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; BLOOD COAGULATION; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLASMINOGEN; PROTHROMBIN;

EID: 0035043257     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120301666980003     Document Type: Article

References (32)

1. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men
2. Antiphospholipid antibody syndrome: Immunologic and clinical aspects
3. Immunology and clinical importance of antiphospholipid antibodies
4. The antiphospholipid syndrome: Ten years on
5. Antibodies to plasma phospholipid-binding proteins and occurrence of thrombosis in patients with systemic lupus erythematosus
6. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus
7. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus
8. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men
9. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules
10. The genetic relationships between the kringle domains of human plasminogen, prothrombin, tissue-type plasminogen activator, urokinase and coagulation factor XII
11. Evolutionary origin of numerous kringles in human and simian apolipoprotein(a)
12. Induction of antiphospholipid autoantibodies by immunisation with β2-glycoprotein I (apolipoprotein H)
13. Induction of phospholipid-binding antibodies in mice and rabbits by immunisation with human β2 glycoprotein I or anticardiolipin antibodies alone
14. Immunisation with anticardiolipin cofactor (beta 2-glycoprotein 1) induces experimental antiphospholipid syndrome in naive mice
15. Lupus anticoagulant antibodies: Recognition of phospholipid-binding protein complexes
16. Antibodies to Prothrombin crossreact with plasminogen in patients developing myocardial infarction
17. Lack of functional similarity between complement factor H and anticardiolipin cofactor, β2-glycoprotein I (apolipoprotein H)
18. A kringle-specific monoclonal antibody
19. Immunochemical characterisation of the kringle 4 fragment of human plasminogen
20. Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus
21. Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis
22. Antibodies to FXII in lupus anticoagulant positive patients
23. Association of anti-b2-Glycoprotein I antibodies with lupus-type circulating anticoagulant and tbrombosis in systemic lupus erythematosus
24. Anticoagulant activity of an anti-β2-glycoprotein I antibody is dependent on the presence of β2-glycoprotein I
25. Functional and binding studies of the roles of prothrombin and beta2-glycoprotein I in the expression of lupus anticoagulant activity
26. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin
27. The contribulion of anti-prothrombin antibodies to lupus anticoagulant activity-discrimination between functional and non-functional anti-prothrombin antibodies
28. Inhibition of plasminogen activation by monoclonal antibodies to the kringle 5-B chain segment of human plasminogen
29. Effect of the nephritogenic autoantibody of Heymann's nephritis onplasminogen binding to gp330 and activation by urokinase
30. The presence and significance of some anti-enzyme antibodies (anti-plasminogen, anti-trypsin, antiphospholipase C) in rheumatoid arthritis (rA)
31. Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis
32. Anticardiolipin' autoantibodies recognise β2-glycoprotein I in the absence of phospholipid